Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 15/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16084068 | 0.89 | PKLR (1.00) | PKLRALDH1A1SMN1; SMN2GAAPKM | |
| SCHEMBL16083871 | 0.89 | PKLR (0.82) | PKLRALDH1A1SMN1; SMN2GAAPKM | |
| SCHEMBL16084023 | 0.87 | PKLR (0.78) | PKLRALDH1A1SMN1; SMN2GAAPKM | |
| SCHEMBL16083860 | 0.86 | PKLR (0.82) | PKLRALDH1A1SMN1; SMN2GAAPKM | |
| SCHEMBL16084037 | 0.83 | PKLR (1.00) | PKLR | |
| SCHEMBL16083896 | 0.83 | PKLR (1.00) | PKLR | |
| SCHEMBL16084021 | 0.83 | PKLR (1.00) | PKLR | |
| SCHEMBL16084080 | 0.82 | PKLR (1.00) | PKLRALDH1A1SMN1; SMN2GAAHTT | |
| SCHEMBL16083759 | 0.82 | PKLR (1.00) | PKLR | |
| SCHEMBL16084081 | 0.82 | PKLR (1.00) | PKLRALDH1A1PKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108921-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | PKLR 14/4885ALDH1A1 860/4885SMN1; SMN2 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.